Liminatus Pharma, Inc. (LIMN): Completion of Acquisition or Disposition of Assets

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha

Event · M&A · completed
Role
acquirer
Counterparty
InnocsAI LLC
Consideration
mixed

Facts are quoted from the filing text and checked against it.

Original reporting
Published Jul 6, 2026, 1:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$LIMN
Neutral
medium confidence
Mentioned
$LIMN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LIMNNeutralMed
01

Why it matters

Completion of the merger changes LIMN’s exposure to CAR-T therapy technologies and related IP, and it introduces deal consideration mechanics (large common-stock issuance plus CVRs) that can affect valuation and trading liquidity.

02

Market read

Deal completion plus explicit consideration terms (1.6B shares at $0.20 and CVRs) are actionable for repricing dilution and contingent upside/downside.

03

What to watch

Traders should focus on (1) the final CVR definition/valuation, (2) whether the 1.6B share issuance implies meaningful ownership dilution, and (3) any contingent liabilities or IP/clinical risk transferred with the acquired CAR-T technology.

Relevance 7/10Novelty 6/10Timing: Filed today (2026-07-06) as the deal is marked completed under Item 2.01.

Background

The 8-K references an amended and restated merger agreement dated June 29, 2026, where InnocsAI LLC merges into a wholly owned subsidiary of Liminatus Pharma.

Company-level read

Ticker impact

$LIMNNeutralMedium confidence
Context

Liminatus Pharma’s 8-K states Item 2.01 completion of an asset acquisition/disposition via an amended and restated merger agreement.

Expected impact

Near-term volatility possible as investors reprice deal economics (stock issuance and CVR terms), but direction depends on deal value vs dilution and CVR structure.

Evidence & confidence

The filing confirms completion and specifies the consideration mechanics (1.6B shares at $0.20 plus CVRs), which can drive dilution/CVR expectations even without further deal valuation details in the excerpt.

Market effects

CAR-T technology M&A read-through: continued consolidation/asset transfers can affect deal expectations and valuation benchmarks for small-cap cell-therapy IP holders.

No clear regional macro linkage in the provided text.

Limited based on excerpt; deal is described as CAR-T IP-related with no cross-border regulatory or jurisdictional specifics shown.

Counterpoint

The excerpt lacks the CVR economics and any disclosed valuation rationale; the market may treat this as largely dilution-driven until CVR terms and post-close integration details are clarified.

Key entities

  • Liminatus Pharma, Inc.

    Purchaser in the amended and restated merger agreement; subject of the 8-K and recipient of the completed transaction.

  • InnocsAI LLC

    Company being merged into a wholly owned subsidiary of LIMN; operates in CAR-T therapy technologies and related IP.

  • NamChul Jung

    Members’ representative named in the merger agreement.

Related articles

$LIMNMed

Liminatus Partners with Korean Firm for CAR

Liminatus Pharma partners with Synex Consulting to advance its CAR-T cell therapy in South Korea. The Ministry of Food and Drug Safety authorized a Phase 1/2a clinical study. Liminatus went public via a SPAC last year. Shares are down 8.2% to $4.73, with a $6.4M market cap.

$LIMNMedAI 8/10

Liminatus Pharma Amends Merger Agreement With InnocsAI To Expand Oncology Pipeline

Liminatus Pharma (LIMN) amended its merger agreement with InnocsAI LLC to expand its oncology pipeline. The deal is now expected to close July 2, 2026, before stockholder approval. InnocsAI holders will receive Liminatus common stock and newly designated non-voting convertible preferred issued at $0.20/share, implying ~$320M value, plus CVRs on 20% of future net proceeds.

$AMDMed

AMD aims at NVIDIA with World Labs and Taalas for next-gen AI supremacy

AMD completed acquisitions of World Labs and Taalas, aiming to strengthen its AI capabilities. World Labs, led by Dr. Fei-Fei Li, focuses on spatial AI models, while Taalas specializes in custom silicon for AI. AMD's CEO, Lisa Su, aims to optimize compute platforms and models together. These acquisitions follow NVIDIA's similar moves and could position AMD as a major player in AI infrastructure, with datacenter revenue expected to exceed 80% by 2027.

$PANWMed

Palo Alto Networks Acquires Applied Compute for $4.5 Billion

Palo Alto Networks (PANW) agreed to acquire AI infrastructure startup Applied Compute for $4.5B in an all-stock deal, aiming to integrate AI development with cybersecurity. The transaction, expected to close in Q3 2027, will see Applied Compute's CEO join PANW as Co-Chief AI Officer. Applied Compute reported $100M annualized revenue and a $3.25B private valuation before the acquisition.